Oric Pharma To Launch Human Trial For CD73 Inhibitor Program In Q4

The FDA has signed off Oric Pharmaceuticals Inc's ORIC Investigational New Drug Application (IND) for ORIC-533.
The Company can now proceed into a first-in-human clinical trial in which ORIC-533 will be tested as a single agent in an undisclosed tumor type not currently known to be under clinical evaluation with any other CD73 inhibitor.
Oric will enroll its first patient in this trial during Q4 of 2021.
During Q4 of 2021, the Company plans to host an R&D event to disclose the tumor indication along with the supporting preclinical rationale and data.
ORIC-533 is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.
Read Next: Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors.
Related content: Benzinga's Full FDA Calendar.
Price Action: ORIC stock is up 4.85% at $25.73 during the premarket session on the last check Tuesday.